Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Bactiguard Holding AB (publ)
  6. News
  7. Summary
    BACTI B   SE0005878741


SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Bactiguard : coated Zimmer Biomet trauma implants for infection prevention launched in select EMEA markets

06/15/2021 | 02:31am EDT

The Zimmer Natural Nail (ZNN) Bactiguard implants are now available in Germany, Spain, and the UK, and will be made available to patients and surgeons in other select EMEA (Europe, Middle East and Africa) markets over the summer.

 "Less than two years from the start of our partnership, we are able to offer the ZNN Bactiguard implants to patients and surgeons in Europe. This is a major achievement by our joint development team. I am clearly excited and proud about our partnership with Zimmer Biomet and confident that it will lead to better outcomes and quality of life for patients," says Cecilia Edström, CEO at Bactiguard

In parallel with the launch, Zimmer Biomet is starting a post-market clinical study to collect additional evidence of the ZNN Bactiguard implants achieving reduced post-operative infection rates.

The Bactiguard technology offers an effective and long-lasting solution for improved infection prevention1. The very thin Bactiguard noble metal alloy coating is attached to the surface of ZNN trauma implants. When in contact with fluids, the metals in the coating create a galvanic effect which reduces microbial adhesion.2This means that less bacteria adhere to the device, which reduces the biofilm formation that can lead to infection.3

The Bactiguard technology is clinically proven to reduce infection in other healthcare applications, including urinary catheters, central venous catheters and endotracheal tubes.4

In September 2019, Bactiguard and Zimmer Biomet partnered to develop and launch orthopedic trauma implants with the Bactiguard technology for infection prevention, to prevent post-operative infections. European regulatory clearance for ZNN Bactiguard implants was obtained in January 2021 and the implants are now ready for launch in Europe and select EMEA markets.

For further information:

Read more about ZNN Bactiguard

Cecilia Edström, CEO, phone: +46 72 226 23 28
Melinda de Boer, Zimmer Biomet, phone: +41 78 706 02 37

About Bactiguard
Bactiguard is a Swedish medical device company with a mission to save lives. To achieve this mission, we develop and supply infection prevention solutions which reduce the risk of infections and the use of antibiotics. This way, we save significant costs for healthcare and the society at large.

The Bactiguard technology is based on a thin noble metal alloy coating that prevents bacterial adhesion and biofilm formation on medical devices. Bactiguard offers the technology through licence agreements and our BIP (Bactiguard Infection Protection) portfolio of products. Urinary catheters with Bactiguard's coating are market leaders in the USA and Japan through our licensing partner BD. Bactiguard's product portfolio also includes a non-alcoholic product line for wound care and disinfection. It effectively kills viruses, bacteria and fungi while being biocompatible, pH neutral and tissue friendly. The active ingredient hypochlorous acid is the same substance as the body's immune cells use in their defence against infectious organisms.

Bactiguard is in a strong expansion phase in the markets in Europe, China, India and the Middle East through our own product portfolio and by establishing licensing deals in new therapy areas. Bactiguard has about 180 employees around the world. Its headquarters and one of three production facilities are located in Stockholm, the other two in Malaysia. Bactiguard is listed on Nasdaq Stockholm.
Read more about Bactiguard www.bactiguard.com

About Zimmer Biomet
Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer Biomet is a global leader in musculoskeletal healthcare. We design, manufacture and market orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants; and related surgical products.

We collaborate with healthcare professionals around the globe to advance the pace of innovation. Our products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. Together with healthcare professionals, we help millions of people live better lives.

We have operations in more than 25 countries around the world and sell products in more than 100 countries. For more information visit www.zimmerbiomet.com.

1, 2, 3, 4 - Review of clinical safety of Bactiguard coated products. 4671-0200-REV, 2021. Available on request.




(c) 2021 Cision. All rights reserved., source Press Releases - English

Stocks mentioned in the article
ChangeLast1st jan.
BACTIGUARD HOLDING AB (PUBL) 4.27% 171 Delayed Quote.14.69%
ZIMMER BIOMET HOLDINGS, INC. 3.47% 150.76 Delayed Quote.-5.44%
09/21BACTIGUARD : completes a directed new share issue to AMF, raising approximately SEK 228 mi..
09/14BACTIGUARD : Aniocyn, now available in stores in the Nordic region
09/11BACTIGUARD : Sepsis always starts with an infection – causes at least 11 M deaths gl..
09/07Bactiguard Holding AB Appoints Anders Göransson as CEO
09/07BACTIGUARD : appoints new CEO
08/31BACTIGUARD : recruits Chief Licensing Officer to accelerate growth
08/31Bactiguard Appoints Carl Johan Fredin as Chief Licensing Officer
08/25Bactiguard Announces Extension of Tender Award for Wound Care Products for the Public S..
08/25BACTIGUARD : Extended Malaysian wound care tender
07/15BACTIGUARD : Interim report for Q2 2021
More news
Sales 2020 177 M 20,5 M 20,5 M
Net income 2020 -38,4 M -4,45 M -4,45 M
Net Debt 2020 254 M 29,5 M 29,5 M
P/E ratio 2020 -125x
Yield 2020 -
Capitalization 5 803 M 672 M 673 M
EV / Sales 2019 15,5x
EV / Sales 2020 28,6x
Nbr of Employees -
Free-Float 34,3%
Duration : Period :
Bactiguard Holding AB (publ) Technical Analysis Chart | BACTI B | SE0005878741 | MarketScreener
Technical analysis trends BACTIGUARD HOLDING AB (PUBL)
Short TermMid-TermLong Term
Income Statement Evolution
Managers and Directors
Cecilia Marie Edstr÷m Chief Executive Officer & Director
Gabriella Bj÷rknert Caracciolo Chief Financial Officer & Deputy CEO
Nils Thomas von Koch Chairman
Stefan Grass Chief Medical Officer & Deputy CEO
Sathish Subramaniam Chief Operations Officer